IGNT-

+5%
RSI 42.72
@ .0020 next resistance .0022
MACD is starting 2 step over bullish

news out this morning
I anticipate an above average day

Ignt a strong buy today. News came out this morning. Keep this stock on your radar list. I am currently going to take a position with a few other investors on this company. A good time to buy this stock while the price is low. I expect this stock to break through the 20 day ma of .0021 and bounce hold at the 50 day ma of .0026. good luck to you all!!

Ingen Quarterly Report Shows an Increase in Sales
Revenues Increase 17% Compared to Last Year

.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Wednesday January 20, 2010, 8:15 am EST

YUCAIPA, Calif., Jan. 20, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that the current quarter sales represented an increase of 17.7% from sales in the quarter ended November 30, 2008. Sales were sparked by the introduction of Oxyview Nasal Cannula unit that includes a cannula with Ingen’s Oxyview unit. Additional capital also enabled the company to increase the advertising and marketing of the Oxyview products. Ingen anticipates that the sales of Oxyview will increase from the current quarter’s sales as the Company expands its sales channels.



The total cost of sales for the quarter ended November 30, 2009 has a gross margin of 90.8%. The reported cost of sales for the quarter ended November 30, 2008 had a gross margin of 89.4%. The Company anticipates that its gross margin will continue to stay in the range of the current quarter.



The largest components of Ingen’s SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. The advertising expense increased from zero in the quarter ended November 30, 2008 to $41,090 in the quarter ended November 30, 2009. The Company expects to continue advertising at current levels as it continues to promote Oxyview.



The Company has reduced its debt to the note holders by $2.3M, and expects to reduce the entire balance by March-2010. The company anticipates a share buy-back program for all of its shareholders once the note is paid in full.



The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.



http://www.ingen-tech.com/